Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

US laboratory takes sequencing and microarray equipment

Illumina : 27 January, 2014  (Application Story)
Illumina will supply LabCorp with sequencing and microarray equipment for use in laboratory testing to support north American clinics
US laboratory takes sequencing and microarray equipment


Illumina has entered into a multi-year supply agreement with Laboratory Corporation of America Holdings (LabCorp). The agreement gives LabCorp expanded rights to use Illumina next-generation sequencing (NGS) and microarray equipment and supplies to develop, validate and introduce laboratory-developed tests to clinicians in the United States and Canada.



Under the terms of the agreement, LabCorp will be able to purchase a broader range of Illumina products for the development of new diagnostic tools in multiple specialties, including genetic testing, oncology, transplant medicine and forensics, in addition to other applications. LabCorp is currently using the technology in connection with new human leukocyte antigen (HLA) tests that it plans to introduce this year.



“The Illumina next-generation sequencing platform gives LabCorp the flexibility to develop a wide range of molecular tests,” said Dr Mark Brecher, LabCorp’s Chief Medical Officer. “The HLA typing assays we are developing on Illumina’s family of NGS platforms will provide physicians with the ability to more accurately match bone marrow donors to recipients.”



“We are excited to support LabCorp’s ability to offer more NGS-based tests such as its HLA offering,” said Nicholas Naclerio, Illumina’s Senior Vice President of Corporate & Venture Development. “Illumina is committed to making NGS broadly available for clinical laboratory testing, and this agreement with LabCorp significantly expands the number of clinicians and patients who will have access to improved diagnostic tools and information.”


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo